alexa Genotype 4 Hepatitis C Virus Responds Worse than Genoty
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Special Issue Article

Genotype 4 Hepatitis C Virus Responds Worse than Genotype 1 to 48-Week Combination Treatment with Pegylated Interferon Alpha Plus Ribavirin: a Greek Multi-Centered Study

Savvoula Savvidou1 *, Dimitrios Chrysagis2 , George V Papatheodoridis3 , Spilios Manolakopoulos3,4, Christos Triantos5 and John Goulis1

1Department of Internal Medicine, Hippocration University Hospital of Thessaloniki, Greece

2Department of Internal Medicine, Infectious Diseases Hospital of Thessaloniki, Greece

3Department of Internal Medicine, Athens University Medical School, Hippocration General Hospital of Athens, Greece

4Department of Gastroenterology, Polyclinic General Hospital of Athens, Greece

5Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, Greece

*Corresponding Author:
Savvidou Savvoula, M.D, M.Sc, Ph.D
Department of Internal Medicine
Hippocration University Hospital of Thessaloniki
49 Konstantinoupoleos Street
and 54629, Thessaloniki, Greece
Tel: +306977774301
E-mail: [email protected]

Received Date: October 24, 2013; Accepted Date: November 22, 2013; Published Date: November 26, 2013

Citation: Savvoula S, Dimitrios C, George PV, Spilios M, Christos TK (2013) Genotype 4 Hepatitis C Virus Responds Worse than Genotype 1 to 48-Week Combination Treatment with Pegylated Interferon Alpha Plus Ribavirin: a Greek Multi-Centered Study. J Antivir Antiretrovir S3:006. doi: 10.4172/jaa.S3-006

Copyright: © 2013 Savvoula S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Prevalence of genotype 4 chronic hepatitis C is increasing in western countries, where response to current combination treatment is still in debate; reports from endemic areas of Middle East show favourable treatment outcomes, while European reports show the contrary. Aim of this retrospective study was to estimate sustained virological response (SVR) of genotype 4 HCV patients in Greece, and to examine possible differences in SVR determinants between genotypes 1 and 4, the two most difficult genotypes to treat.
Methods: Demographic, virological and histological data from 467 consecutive HCV patients from five centers of follow-up were recorded. All patients completed standard combination therapy with pegylated interferon alpha plus weight-based ribavirin, according to current guidelines.
Results: Genotype distribution was: 192(44.8%), 29(6.8%), 130(30.4%), 63(14.7%) and 14(3.3%) for 1, 2, 3, 4 and undefined genotypes, respectively. Baseline characteristics were: 245(57.2%) male, aged 44.8 ± 13.8 years-old, 422(98.6%) white Caucasians, 124(29%) former intravenous drug users, 49(12%) past alcohol abusers, 240(51.5%) overweight and 357(87.7%) naïve. Liver biopsy revealed advanced fibrosis in 58(15.1%) and hepatic steatosis in 133(35.6%) patients. Age (OR 2.1, p=0.007), genotype (OR 3.4, p<0.001), advanced fibrosis (OR 2.9, p=0.003) and naïve status (OR 0.3, p<0.001) were independent prognostic factors for non-response. Comparison between genotype 4 and 1 revealed significant differences in SVR (39.7% vs. 62%, Fisher’s exact test, p=0.002). No difference related to any of the demographic, virological or histological variable was able to explain the difference in treatment response.
Conclusion: Genotype 4 chronic hepatitis C in Greece has the worst prognosis in achieving SVR using current combination treatment for 48 weeks. These results challenge the notion, mainly from non-european studies, of a favorable response of genotype 4 compared to genotype 1. Further studies addressing the efficacy of the newer antivirals on the “difficult to treat” genotype 4 should be investigated in the future.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords